Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:abusePotential |
high
|
| gptkbp:activeIngredient |
gptkb:oxycodone
|
| gptkbp:approvedBy |
1990s
|
| gptkbp:ATCCode |
N02AA05
|
| gptkbp:contraindication |
acute asthma
paralytic ileus severe respiratory depression |
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II_(US)
|
| gptkbp:drugClass |
opioid
|
| gptkbp:eliminationHalfLife |
3-4.5 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
5 mg
15 mg 30 mg immediate-release tablet |
| gptkbp:genericAvailable |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Roxicodone
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Mallinckrodt_Pharmaceuticals
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:riskFactor |
addiction
overdose |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
constipation drowsiness respiratory depression |
| gptkbp:usedFor |
pain management
|
| gptkbp:bfsParent |
gptkb:oxycodone
gptkb:Oxycodone |
| gptkbp:bfsLayer |
7
|